Published in:
Open Access
01-12-2018 | Editorial
Didn’t inhale? Time to reconsider aerosolized antibiotics in the treatment of ventilator-associated pneumonia
Authors:
Daniel A. Sweeney, Andre C. Kalil
Published in:
Critical Care
|
Issue 1/2018
Login to get access
Excerpt
“The War on Drugs” in the 1970s had an unintended effect on the illegal cannabis industry, increasing domestic production such that cannabis has become among the most profitable cash crops in the United States [
1]. Legal barriers to cannabis use are also steadily crumbling: 30 states have legalized medical marijuana and nine states permit recreational use [
2]. Yet despite its economic impact and increasing mainstream use, the safety and merits of cannabis consumption have not been rigorously studied. Is cannabis an effective antiepileptic or does it cause seizures? How is it possible that cannabis is touted as an anti-emetic, yet cannabinoid hyperemesis syndrome is reported in the medical literature? The answers to these questions likely relate to dose, mode of delivery, and patient selection—the very same questions at the root of whether inhaled antibiotics are an effective therapy for ventilator-associated pneumonia (VAP). …